Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX.
Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX.
Am J Obstet Gynecol. 2021 May;224(5):484-495. doi: 10.1016/j.ajog.2021.01.022. Epub 2021 Jan 30.
The coronavirus disease 2019 has caused over 2 million deaths worldwide, with over 412,000 deaths reported in Unites States. To date, at least 57,786 pregnant women in the United States have been infected, and 71 pregnant women have died. Although pregnant women are at higher risk of severe coronavirus disease 2019-related illness, clinical trials for the available vaccines excluded pregnant and lactating women. The safety and efficacy of the vaccines for pregnant women, the fetus, and the newborn remain unknown. A review of maternal and neonatal coronavirus disease 2019 morbidity and mortality data along with perinatal vaccine safety considerations are presented to assist providers with shared decision-making regarding vaccine administration for this group, including the healthcare worker who is pregnant, lactating, or considering pregnancy. The coronavirus disease 2019 vaccine should be offered to pregnant women after discussing the lack of safety data, with preferential administration for those at highest risk of severe infection, until safety and efficacy of these novel vaccines are validated.
新型冠状病毒病 2019 在全球已导致超过 200 万人死亡,美国报告的死亡人数超过 41.2 万。截至目前,美国至少有 57786 名孕妇感染,71 名孕妇死亡。尽管孕妇患严重新型冠状病毒病 2019 相关疾病的风险更高,但现有的疫苗临床试验将孕妇和哺乳期妇女排除在外。孕妇、胎儿和新生儿接种疫苗的安全性和有效性仍不清楚。本文回顾了孕产妇和新生儿新型冠状病毒病 2019 发病率和死亡率数据,并对围产期疫苗安全性进行了考虑,以帮助提供者就该人群的疫苗接种做出共同决策,包括怀孕、哺乳期或考虑怀孕的医护人员。在讨论缺乏安全性数据后,应向孕妇提供新型冠状病毒病 2019 疫苗,并优先为感染严重疾病风险最高的人群接种,直到这些新型疫苗的安全性和有效性得到验证。